Literature DB >> 2972815

Demonstration of reperfusion after thrombolysis with technetium-99m isonitrile myocardial imaging.

D S Kayden1, J A Mattera, B L Zaret, F J Wackers.   

Abstract

Technetium-99m isonitrile myocardial perfusion imaging was employed in a patient undergoing thrombolytic therapy with recombinant tissue plasminogen activator for acute anteroseptal myocardial infarction. Technetium-99m isonitrile does not demonstrate significant myocardial redistribution after intravenous injection. The imaging agent was administered in the emergency room, prior to the initiation of thrombolytic therapy. The initial area at risk for infarction was visualized on images obtained after the patient had been effectively treated. Imaging performed 5 days later, after repeat injection of [99mTc]isonitrile, showed a smaller myocardial perfusion defect indicating salvage of myocardium. Thus, this technique offers promise as a noninvasive means of assessing the area at risk, the success of reperfusion, and the presence of salvaged myocardium, early in the course of acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2972815

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  4 in total

Review 1.  An overview of radiotracers in nuclear cardiology.

Authors:  W Acampa; C Di Benedetto; A Cuocolo
Journal:  J Nucl Cardiol       Date:  2000 Nov-Dec       Impact factor: 5.952

2.  Effect of coronary reperfusion on technetium-99m methoxyisobutylisonitrile uptake by viable and necrotic myocardium in the dog.

Authors:  Y Merhi; J G Latour; A Arsenault; G Rousseau
Journal:  Eur J Nucl Med       Date:  1992

Review 3.  Technetium-labeled myocardial imaging agents.

Authors:  A S Iskandrian; J Heo
Journal:  Int J Card Imaging       Date:  1992

4.  99mTc-sesta-(2-methoxy-isobutyl-isonitrile) uptake by pancreatic islets, parotid cells, and mammary carcinoma cells.

Authors:  D Blocklet; H Jijakli; A Sener; A Schoutens; W J Malaisse
Journal:  Endocrine       Date:  1998-08       Impact factor: 3.925

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.